

Perspective

Cite this article: Koning E, Chu EM, and Brietzke E (2024). The historical opposition to psychedelic research and implications for credibility in psychiatry. *CNS Spectrums* <https://doi.org/10.1017/S1092852924002141>

Received: 15 April 2024

Accepted: 05 September 2024

Keywords:


psychedelics; psychotherapy; psychiatry; neuroscience; history; drug policy

Corresponding author:

Elena Koning;

Email: elena.koning@queensu.ca

The historical opposition to psychedelic research and implications for credibility in psychiatry

Elena Koning^{1,2} , Elvina M. Chu^{1,2} and Elisa Brietzke^{1,2}

¹Department of Psychiatry, Queen's University School of Medicine, Kingston, ON, K7L 2V7, Canada and ²Centre for Neuroscience Studies, Queen's University, Kingston, ON, K7L 2V7, Canada.

Abstract

Psychedelics are a group of psychoactive substances that alter consciousness and produce marked shifts in sensory perception, cognition, and mood. Although psychedelics have been used by indigenous communities for centuries, they have only recently been investigated as an adjunctive therapeutic tool in psychotherapy. Since the early twentieth century, psychedelic-assisted psychotherapy has been explored for the treatment of several neuropsychiatric conditions characterized by rigid thought patterns and treatment resistance. However, this rapidly emerging field of neuroscience has evolved alongside opposition in several areas, including the affiliation with mid-twentieth century counterculture movements, media sensationalization, legislative restriction, and scientific criticisms such as “breaking the blind” and “excessive enthusiasm.” This perspective article explores the historical opposition to psychedelic research and the implications for the credibility of the field. In the midst of psychedelic drug policy reform, drawing lessons from historical events will contribute to clinical research efforts in psychiatry.

Introduction

The term *psychedelics* was named by psychiatrist Humphrey Osmond in 1957, an etymology that suggests a ‘mind-manifesting’ capability. Modernly, they can be defined as a group of substances that alter consciousness in a complex and subjective manner. The classical psychedelics include lysergic acid diethylamide (LSD), dimethyltryptamine (DMT), psilocybin, and mescaline, which act primarily as a 5-HT_{2A} receptor agonist, especially in high-level cortical areas.^{1,2} Nonclassical psychedelics include 3,4-methylenedioxymethamphetamine (MDMA), which nonselectively activates monoamine receptors and promotes serotonin neurotransmission as well as the dissociative anesthetic and N-methyl-D-aspartate receptor antagonist ketamine. Although there are a variety of origins and chemical structures, the perceived effects of psychedelics are relatively similar, including marked shifts in perception, cognition, and mood.³ Mechanistically, psychedelics cause serotonergic stimulation and disrupt functional connectivity in brain networks such as the default mode network and between regions of the frontal cortex and subcortical areas.^{1,4,5}

Psychedelics have been used for centuries by indigenous communities and have played a role in many cultures in the ancient Northern, Central, and Southern Americas.⁶ In modern research, they are typically administered as an adjunct to psychotherapy, in a model known as psychedelic-assisted psychotherapy (PAP), with preparation and integration sessions occurring before and after dosing, respectively. The context for PAP is thoughtfully curated with relaxing music, a living-room ambience and psychological support from a therapist.⁷ In this way, it has been investigated as a potential treatment for several neuropsychiatric disorders. For example, meta-analyses reveal large effect sizes of psilocybin-assisted psychotherapy on improved depressive and anxiety symptoms,^{8–11} MDMA-assisted psychotherapy has demonstrated high rates of tolerability, clinical response, and remission in individuals with PTSD symptoms,¹² and the therapeutic effects of psychedelics have been preliminarily investigated in eating disorders, cluster headaches, and Alzheimer's disease.^{13–16}

Throughout history, psychedelic research has evolved alongside opposition and controversy, including questionable scientific practices, exaggerated safety risks, and associations with counterculture movements that have contributed to stigmatization. Further, there is a long-standing debate over the dangers and therapeutic efficacy of psychedelics.

Twentieth century opposition to psychedelic research

The rapidly evolving timeline of psychedelic research, as depicted in [Figure 1](#), was stimulated by the discovery of psychoactive properties of LSD by chemist Albert Hoffmann of Sandoz Pharmaceuticals in 1943.^{17,18} Sandoz Pharmaceuticals contributed to a fertile period of

© The Author(s), 2024. Published by Cambridge University Press. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.




Figure 1. The timeline of notable historical events related to psychedelic research impacted the credibility of this emerging field in psychiatry. Abbreviations: LSD, Lysergic acid diethylamide; JAMA, Journal of the American Medical Association; US, United States; UN, United Nations; MDMA, 3,4-methylenedioxymethamphetamine.

psychedelic research in the 1950s, including the identification of psilocybin in magic mushrooms by Hofmann in 1958.^{19,20} LSD was widely used as an adjunct to psychotherapy for a period of about 15 years and it was reported that up to 79% of mood disorder patients demonstrated subjective clinical improvement.^{19,21} Throughout the 1950s, psychedelic research occurred with limited opposition or government oversight. In fact, over 130 clinical study grants were government-funded.²²

Despite emerging therapeutic interest in psychedelics, many early trials faced skepticism. Major methodological biases were highlighted, including the lack of standardized measures, randomization procedures, adequate sample characteristics, and controlling which limited the validity of the results. Jonathan Cole, president of the American College of Neuropsychopharmacology (1965–66), was one of the first scientists to voice criticism of psychedelic research, emphasizing the lack of evidence for safety and efficacy.^{23(p19),24} However, scientific opposition was not the only avenue in which psychedelic research was discredited.

During the early era of psychedelic research, recreational use increased substantially, especially amongst individuals engaging in the counterculture movement of the 1960s. The psychedelic-associated counterculture movement faced opposition by supporters of the U.S. involvement in the Vietnam, Laos and Cambodia war (1955–1975). Political figures such as President Richard Nixon and President Lyndon B. Johnson voiced opposition to the psychedelic counterculture, claiming the necessity of the war and the importance of upholding patriotic duty. The first major advancements in the development of psychotropic pharmacotherapies occurred around the same time, but these were not met with the same political opposition.²⁵

Timothy Leary was a Harvard psychologist and prominent figure in mid-twentieth century psychedelic counterculture. After undergoing a personal experience with psilocybin in Cuernavaca, Mexico, Leary conducted research on the effects of psychedelics at Harvard University alongside colleague Richard Alpert, advocating for the ability of psychedelics, particularly LSD, to expand consciousness and promote psychological benefits. Leary conducted multiple unapproved projects and widely encouraged psychedelic use by the public, famously quoting “turn on, tune in, drop out.” Both Leary and Alpert were dismissed for these actions from Harvard University in 1963, and the continued promotion of psychedelics eventually led to Leary’s arrest in 1966.¹ President

Richard Nixon referred to Leary as “the most dangerous man in America,” with increasing concerns that recreational psychedelic use would pose health concerns and jeopardize war efforts in Vietnam. However, Leary was not alone in advocating for the psychedelic movement. Many other prominent figures including novelists Aldous Huxley and Ken Kesey as well as popular bands such as The Doors and The Beatles contributed.^{26,27}

Despite emerging political and scientific opposition, the recreational use of psychedelics continued, often in uncontrolled environments. Further, there was an increase in the illegitimate use of psychedelics by sham psychiatrists.²⁸ The concept of the “bad trip” began to be recognized, referring to negative and distressing psychedelic experiences and contributing to the existing negative perception. However, this was not the first incidence of cultural opposition to psychedelics. Antipsychedelic views were often shared by several religious groups campaigning against Native American peyote use and referring to the substances as “addictive” and “insidious evil.”²⁹

Sensationalist media coverage of psychedelic medicines highlighted the emerging safety concerns associated with these substances, including reports of psychosis, accidental death, and suicide among users.²⁷ LSD was first banned in California in the mid-1960s as a result of these growing public concerns.³⁰ In 1969, the adverse public narrative of psychedelics was further perpetuated by the case of Charles Manson, a cult leader who used LSD to convince his followers to partake in mass homicide.²⁷ The concept of psychedelic neurotoxicity also emerged in which reports suggested that psychedelic users exhibit neurological or cognitive deficits.^{31,32} Individuals advocated for stricter regulations on the clinical use of LSD in response to adverse events among patients undergoing psychotherapy.^{28,27,33}

In 1963, the US Federal legislation increased restrictions on pharmaceutical research, requiring ethics approval in the form of a Clinical Trial Notification, which requires methodologically sound preclinical evidence of safety and efficacy.^{34,35} In response to emerging controversy, Sandoz Pharmaceutical withdrew sponsorship of psychedelic trials in 1965.^{17,34} At this point, psychedelic research was limited to studies funded by the National Institute of Health (NIH). The United Nations classified LSD, psilocybin, and mescaline as Schedule I in 1967, considering them as substances with no or very little medical purpose, a high potential for abuse, and a lack of accepted safety.³⁶ Similar political changes occurred in

other countries, including Schedule 3 status under the Controlled Drugs and Substances Act in Canada.^{36,37}

This political and legal opposition led to an unprecedented restriction on research efforts for decades, making it difficult for researchers to conduct studies using psychedelics, with limited funding and resources available. However, a few studies were conducted as supported by the Food and Drug Administration and NIH.^{34,38} Nonetheless, the political opposition to psychedelic research that occurred was unprecedented in the field of psychiatry. This is especially true considering the growing body of positive findings that occurred leading up to scheduling and the relatively favorable safety profile of psychedelics in medically supervised contexts.^{22,36,37}

The use and study of psychedelics largely occurred “underground” throughout the remainder of the twentieth century, leading to the conduct of methodologically and ethically questionable practices and therapeutic models. For example, some therapists conducted PAP with substances obtained from the illicit market.³⁹ Reports also include the use of therapeutic touch as a crucial aspect of practice, raising concerns about boundary violation and misconduct. Unethical conduct even extended to administering high doses of LSD to unprepared, restrained patients.⁴⁰

Psychedelic research dwindled for decades until around the turn of the twenty-first century when a renewed scientific interest emerged in their therapeutic potential. Advancements in neuroscience such as neuroimaging techniques and psychopharmacological studies in healthy individuals contributed to the study of psychedelics in the modern age. In addition, small exploratory studies conducted at the early stages provided a base for larger investigations. For example, Rick Strassman and colleagues investigated DMT in the first government-approved study, which illustrated the importance of ‘set’ and ‘setting.’⁴¹ Roland Griffiths and colleagues demonstrated the profound and mystical nature of the psychedelic experience.^{42,43} The first modern clinical trial was a pilot study conducted by Moreno et al (2006) on psilocybin for treatment-resistant obsessive-compulsive disorder. Significant reductions (23–100%) in symptoms occurred in all participants without adverse events, although the improvements did not last.⁴⁴ Many other impactful and pioneering studies occurred during this period of psychedelic research resurgence.²²

Sociocultural factors impacting psychedelic research credibility

Despite significant cultural normalization, there remains a social stigma against psychedelics, amongst persisting antidrug views. The classification of psychedelic substances as Schedule I has been a contributor, which also includes an exaggeration of their risks and addictive potential, contrary to the evidence.³⁶ Ironically, psychedelics have actually demonstrated preliminary efficacy in the treatment of addiction and substance use disorders.^{10,11,45} Previous work has shown that public views of high toxicity and adverse events are largely incorrect.^{46–51} Further, the illegal status has contributed to the “underground” use of these substances, which further stigmatizes them in the public eye.

The medicalization of psychedelics as an adjunct to psychotherapy is contributing to a more positive cultural opinion. However, the “hype” surrounding psychedelic research is disproportionate to the available evidence and threatens public credibility if results do not follow through. Yaden (2022) described the “The Gartner Hype Cycle” in which novel scientific advancements trigger substantial

public attention, leading to inflated expectations followed by a steep decline when expectations are not met in which public narratives may shift from overly positive to overly negative, before a plateau occurs.⁵²

“Excessive enthusiasm” refers to the influence of personal use of psychedelics by researchers, potentially compromising scientific objectivity and promoting the biased reporting of results.⁵³ Cole & Katz (1964) were one of the first to describe “excessive enthusiasm.”²⁴ Today, concerns of researcher bias persist, as discussed in a recent paper titled “Should we be leery of being Leary?”⁵³ “Excessive enthusiasm” may also impact the credibility of psychedelic research at the participant level. Individuals with past psychedelic experiences may be more likely to partake in psychedelic research, to expect positive results and to “break the blind.” This may lead to a self-selecting study population, introducing bias into psychedelic research and ultimately jeopardizing credibility.

Political factors impacting psychedelic research credibility

Legislative restrictions of the 1960s and 1970s were largely made before a thorough understanding of the pharmacological effects of psychedelics was reached, leading to vague reasoning. Ongoing debates about the Schedule I classification of psychedelics highlight significant discrepancies in regulatory criteria, summarized by Nutt et al (2013).³⁶ Although preliminary interest in the therapeutic potential of psychedelic substances was identified by the 1960s, Schedule I criteria claims that there is no or very little medical purpose. At this point, there was evidence of safety for the use of psilocybin under medical supervision, and further investigations to determine the safety and efficacy cannot be conducted due to scheduling.³⁶ In this way, criteria for Schedule I status is paradoxically self-fulfilling as restrictions on research prevent the conduct of safety and efficacy studies that are necessary to challenge the classification.

While there are certainly unique risks associated with psychedelics, many argue that scheduling appears to be based on the assumption of extreme risk. Interestingly, an analysis demonstrated no relationship between the level of harm of psychoactive substances and legal status.^{50,51} The “War on Drugs” launched by the Nixon administration disproportionately targeted marginalized groups and low-income communities, including selective enforcement, racial profiling, and over-incarceration with limited harm-reduction programs.⁵⁴ John Ehrlichman, the domestic policy chief for Nixon, was famously quoted in a 1994 interview stating that the administration’s drug policies were intentionally crafted to disrupt and vilify certain communities, irrespective of drug harm. The political narrative of “protecting” the public from psychedelics is especially ironic considering the disturbing MK-Ultra project in which the CIA experimented if LSD could be used for “brain-washing” individuals.⁵⁵ In this way, legislative restrictions on psychedelics were made due to a confluence of factors beyond safety concerns or scientific evidence alone.

The scheduling of psychedelics from the 1970s persists in the majority of North America today. In Canada, LSD, psilocybin and psilocin, mescaline, and DMT remain as Schedule 3 substances, while MDMA and ketamine are Schedule 1, impacting the conduct of psychedelic research at numerous levels. For example, granting agencies may be reluctant to fund psychedelic research initiatives due to the misconceptions surrounding safety.³⁶ Further, the illegal status of psychedelics makes it difficult to gain approval for their use in clinical research. The Multidisciplinary Association for Psychedelic Studies took over four years to gain approval to investigate the therapeutic

use of MDMA for PTSD, due to legislative hurdles enacted by Health Canada and institutional review boards.³⁶

The status of these substances applies to any quantity, challenging research on submilligram doses, a fear that may be associated with the “leaking” of psychedelic substances into the recreational domain in the mid-twentieth century.³⁶ The restrictions extend to other 5-HT_{2A} agonists, limiting adjacent lines of research which may improve the mechanistic understanding of psychedelics.^{4,43,56} Even once legislative hurdles are overcome, it is difficult to source pharmaceutical-grade psychedelics for research. Manufacturers face numerous hurdles in the development of psychedelics, leading to high costs of custom synthesis that is often too extensive for research grants, \$12,000 per gram of psilocybin, for example.⁵⁶ Together, numerous political and legal barriers continue to impact the ability to conduct psychedelic research.

Scientific factors impacting psychedelic research credibility

The final area in which psychedelics have faced historical opposition and continue to impact the credibility of the field is through the level of scientific opinion. The “underground” nature in which psychedelics were studied and used throughout the latter half of the twentieth century contributes to skepticism about the scientific validity of the therapeutic claims resulting from this era of psychedelic research. Many early studies were later refuted and retracted.^{32,57,58} As an evolving field of neuroscience, psychedelic research faces several challenges that are inherent to clinical, neuropharmacological, and psychotherapeutic research fields; in particular, adhering to the accepted gold-standard framework of the randomized controlled trial (RCT).

PAP clinical trials are typically conducted with relatively small sample sizes due to the amount of time and resources required. The absence of a control group is another limitation. Open-label, uncontrolled studies which report reductions in illness severity following PAP are not sufficient to prove efficacy. Another criticism related to sample characteristics is the often-extensive exclusion criteria, excluding participants with comorbidities, drug use, or a family history of psychotic disorders. While there are important safety precautions to uphold, it is argued that populations participating in psychedelic trials are easier to treat.⁵⁹ Further, participants of psychedelic studies are typically Caucasian with socioeconomic stability, limiting generalizability and external validity.⁶⁰ Many psychedelic studies have been conducted as a single session with minimal follow-up, threatening construct validity by making it difficult to determine if the benefit is persistent.⁵⁹

Another methodological criticism is expectancy bias, a form of cognitive bias in which an individual’s expectations about a process or outcome may influence the perception of their own or someone else’s behavior.⁶¹ Expectancy, including “excessive enthusiasm,” may occur in psychedelic research at the level of the participant, investigator, or therapist and may be responsible for a portion of the therapeutic outcomes observed.^{24,53} For example, therapist positive beliefs about psilocybin have been associated with greater openness to involving patients with PAP. Likewise, participants with positive beliefs about psychedelics are more likely to volunteer.⁶² Expectancy may also contribute to negative outcomes if participants expecting a psychedelic experience in the control arm become disappointed upon being informed of their allocation.⁶³ Expectation bias in psychedelic research has not been fully investigated.⁶⁴

In the RCT, expectancy is typically overcome through double-blinding, in which neither the researcher administering the

substance or the participant is aware of their group allocation. However, blinding is particularly difficult to achieve in psychedelic research, due to perceptual distortions and hallucinations.⁶¹ ‘Breaking the blind’ is a challenge across psychedelic research, which threatens internal validity as blinding cannot be achieved. Different study designs have attempted to overcome this limitation, such as employing multiple doses to standardize expectation and preparation procedures across study arms or including an active comparator, such as ketamine.^{1,65,66}

The lack of mechanistic understanding of psychedelics is another scientific criticism that limits the credibility of the field. It is difficult to determine the components eliciting any therapeutic outcomes, threatening validity. For example, mysticism, interoception, and cognitive flexibility are prominent in the psychedelic experience but are difficult to isolate and measure objectively.^{67–69} Furthermore, the psychedelic experience displays inter-individual variability and is context-dependent, producing different outcomes depending on expectancy, the environment and drug administration. Some argue that therapeutic benefits can be attributed, in part, to the music played during dosing or primarily from the psychological support.^{22,70} It is possible that cognitive, psychological, and neurobiological changes elicited by psychedelics play independent or convergent roles in therapeutic outcomes.

Current ethical concerns include the ineffable and variable nature of the psychedelic experience, making it difficult to obtain fully informed consent.^{71,72} Another concern is the state of high psychological vulnerability elicited by psychedelics. Historically, the inappropriate use of therapist power, including sexual misconduct, has occurred in psychedelic clinical trials.⁵⁹ It is important for specific PAP guidelines and regulatory frameworks to be developed for ethical conduct.

Together, numerous scientific criticisms limit the credibility of modern psychedelic research and efforts to address these methodological limitations remain largely unsuccessful.⁷³ As the field progresses, the increased compliance of psychedelic studies with rigorous clinical research protocols has and will contribute to the increased credibility of the field, something that is important to uphold and improve in future work.⁷

Conclusions

Although the historical events described here have and continue to impact the credibility of the field, advancements in psychedelic research continue. Rescheduling appears to be a logical next step to conduct research and determine the safety and efficacy of these substances, although there are numerous hurdles which need to be overcome. Nonetheless, legislative changes are occurring across North America. Denver was the first U.S. city to decriminalize psilocybin, and Oregon legalized the medical use of psilocybin in 2020. Twenty-five U.S. states have considered 75 bills in which 10 were enacted and 32 are still active regarding psychedelic legislation reform.⁷⁴ Regardless, the field is still in its infancy, and few high-quality studies have been conducted, raising concerns over the premature nature in which political changes may occur.^{75–81}

At a crucial time in drug policy reform, it is important to consider how to minimize the risk for setbacks and further detriments to the credibility of psychedelic research. For example, there is a concern for how stakeholder interests could impact credibility due to increasing financial conflicts of interest in psychedelic research and reporting.⁸² Simultaneously, if the commercialization model of psychedelics fails, then there is a concern that funding for research efforts will be halted, ultimately creating another setback

for research efforts.^{36,39,81,83} Culturally, inflated expectations and the sensationalization of psychedelic therapy may pose safety risks and contribute to disappointment in the field.⁵² It remains to be determined how regulatory bodies will continue to control psychedelics upon reform and how political, legislative, and cultural factors will continue to impact credibility. In drawing lessons from historical events, legislative decisions should be conducted with public health and safety as a top priority, guided by methodologically sound evidence.

Acknowledgements. None.

Author contribution. Conceptualization: E.C.; Formal analysis: E.K.; Investigation: E.K.; Methodology: E.K.; Project Administration: E.K.; Supervision: E.B.; Writing—original draft: E.K.; Writing—review and editing: E.K., E.C., E.B.

Competing interest. None.

References

- Carhart-Harris RL, Goodwin GM. The therapeutic potential of psychedelic drugs past, present, and future. *Neuropsychopharmacology*. 2017;**42**(11):2105–2113. doi:10.1038/npp.2017.84
- Mayet S. A review of common psychedelic drugs. *South Afr J Anaesth Analg*. 2020;**26**(6):S113–117.
- Nichols DE. Psychedelics. *Pharmacol Rev*. 2016;**68**(2):264–355. doi:10.1124/pr.115.011478
- Carhart-Harris RL, Erritzoe D, Williams T, et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. *Proc Natl Acad Sci U S A*. 2012;**109**(6):2138–2143. doi:10.1073/pnas.1119598109
- Carhart-Harris R, Nutt D. Serotonin and brain function: a tale of two receptors. *J Psychopharmacol Oxf Engl*. 2017;**31**(9):1091–1120. doi:10.1177/0269881117725915
- Guerra-Doce E. Psychoactive substances in prehistoric times: examining the archaeological evidence. *Time Mind*. 2015;**8**(1):91–112. doi:10.1080/1751696X.2014.993244
- Nutt D, Spriggs M, Erritzoe D. Psychedelics therapeutics: what we know, what we think, and what we need to research. *Neuropharmacology*. 2023;**223**:109257. doi:10.1016/j.neuropharm.2022.109257
- Goldberg SB, Pace BT, Nicholas CR, Raison CL, Hutson PR. The experimental effects of psilocybin on symptoms of anxiety and depression: a meta-analysis. *Psychiatry Res*. 2020;**284**:112749. doi:10.1016/j.psychres.2020.112749
- Johannesdottir A, Sigurdsson E. The use of psilocybin for treatment-resistant depression. *Laeknabladid*. 2022;**108**(9):403–410. doi:10.17992/lbl.2022.09.706
- Dos Santos RG, Bouso JC, Alcázar-Córcoles MÁ, Hallak JEC. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews. *Expert Rev Clin Pharmacol*. 2018;**11**(9):889–902. doi:10.1080/17512433.2018.1511424
- Hodge AT, Sukpraprut-Braaten S, Narlesky M, Strayhan RC. The use of psilocybin in the treatment of psychiatric disorders with attention to relative safety profile: a systematic review. *J Psychoactive Drugs*. 2023;**55**(1):40–50. doi:10.1080/02791072.2022.2044096
- Bahji A, Forsyth A, Groll D, Hawken ER. Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder: a systematic review and meta-analysis. *Prog Neuropsychopharmacol Biol Psychiatry*. 2020;**96**:109735. doi:10.1016/j.pnpbp.2019.109735
- Calder A, Mock S, Friedli N, Pasi P, Hasler G. Psychedelics in the treatment of eating disorders: rationale and potential mechanisms. *Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol*. 2023;**75**:1–14. doi:10.1016/j.euroneuro.2023.05.008
- Rusanen SS, De S, Schindler EAD, Artto VA, Storvik M. Self-reported efficacy of treatments in cluster headache: a systematic review of survey studies. *Curr Pain Headache Rep*. 2022;**26**(8):623–637. doi:10.1007/s11916-022-01063-5
- Kozłowska U, Nichols C, Wiatr K, Figiel M. From psychiatry to neurology: psychedelics as prospective therapeutics for neurodegenerative disorders. *J Neurochem*. 2022;**162**(1):89–108. doi:10.1111/jnc.15509
- Pilozzi A, Foster S, Mischoulon D, Fava M, Huang X. A brief review on the potential of psychedelics for treating Alzheimer's disease and related depression. *Int J Mol Sci*. 2023;**24**(15):12513. doi:10.3390/ijms241512513
- Hofmann A. LSD: my problem child – reflections on sacred drugs, mysticism and science. <https://www.goodreads.com/en/book/show/8791>. Published 1980. Accessed February 3, 2024.
- Stoll WA. Lysegsaure-diethylamid, ein Phantastikum aus der Mutterkorngruppe. https://archives.lib.purdue.edu/repositories/2/archival_objects/26027. Published 1947. Accessed February 3, 2024.
- Grinspoon L, Bakalar JB. The psychedelic drug therapies. *Curr Psychiatr Ther*. 1981;**20**:275–283.
- Hofmann A, Heim R, Brack A, Kobel H. Psilocybin, a psychotropic substance from the Mexican mushroom *Psilocybe mexicana* Heim. *Experientia*. 1958;**14**(3):107–109. doi:10.1007/BF02159243
- Rucker JJ, Jelen LA, Flynn S, Frowde KD, Young AH. Psychedelics in the treatment of unipolar mood disorders: a systematic review. *J Psychopharmacol Oxf Engl*. 2016;**30**(12):1220–1229. doi:10.1177/0269881116679368
- Nutt D. Psychedelic drugs—a new era in psychiatry? *Dialogues Clin Neurosci*. 2019;**21**(2):139–147. doi:10.31887/DCNS.2019.21.2/dnutt
- Mangini M. Treatment of alcoholism using psychedelic drugs: a review of the program of research. *J Psychoactive Drugs*. 1998;**30**(4):381–418. doi:10.1080/02791072.1998.10399714
- Cole JO, Katz MM. The psychotomimetic drugs: an overview. *JAMA*. 1964;**187**(10):758–761. doi:10.1001/jama.1964.03060230086021
- Braslow JT, Marder SR. History of psychopharmacology. *Annu Rev Clin Psychol*. 2019;**15**:25–50. doi:10.1146/annurev-clinpsy-050718-095514
- Jay M. Mescaline: a global history of the first psychedelic. *Soc Hist Alcohol Drugs*. 2019;**34**(2):372–375. doi:10.1086/710634
- Hall W. Why was early therapeutic research on psychedelic drugs abandoned? *Psychol Med*. 2022;**52**(1):26–31. doi:10.1017/S0033291721004207
- Novak SJ. LSD before Leary. Sidney Cohen's critique of 1950s psychedelic drug research. *Isis Int Rev Devoted Hist Sci Its Cult Influ*. 1997;**88**(1):87–110. doi:10.1086/383628
- Newberne REL, Burke CH. *Peyote. An Abridged Compilation from the Files of the Bureau of Indian Affairs*. Washington, Govt. print. off.; 1922. Accessed January 30, 2024. <http://archive.org/details/peyoteabridgedco00unit>
- Siff S. *Acid Hype: American News Media and the Psychedelic Experience*. Champaign, IL: University of Illinois Press; 2015. doi:10.5406/illinois/9780252039195.001.0001
- Schlag AK, Aday J, Salam I, Neill JC, Nutt DJ. Adverse effects of psychedelics: from anecdotes and misinformation to systematic science. *J Psychopharmacol Oxf Engl*. 2022;**36**(3):258–272. doi:10.1177/02698811211069100
- Cohen MM, Marinello MJ, Back N. Chromosomal damage in human leukocytes induced by lysergic acid diethylamide. *Science*. 1967;**155**(3768):1417–1419. doi:10.1126/science.155.3768.1417
- Brecher EM. *Licit and Illicit Drugs: The Consumers Union Report on Narcotics, Stimulants, Depressants, Inhalants, Hallucinogens, and Marijuana - Including Caffeine, Nicotine, and Alcohol*. Boston, MA: Little, Brown; 1972.
- Oram M. Efficacy and enlightenment: LSD psychotherapy and the drug amendments of 1962. *J Hist Med Allied Sci*. 2014;**69**(2):221–250. doi:10.1093/jhmas/jrs050
- Bonson KR. Regulation of human research with LSD in the United States (1949–1987). *Psychopharmacology (Berl)*. 2018;**235**(2):591–604. doi:10.1007/s00213-017-4777-4
- Nutt DJ, King LA, Nichols DE. Effects of schedule I drug laws on neuroscience research and treatment innovation. *Nat Rev Neurosci*. 2013;**14**(8):577–585. doi:10.1038/nrn3530
- Tupper KW, Wood E, Yensen R, Johnson MW. Psychedelic medicine: a re-emerging therapeutic paradigm. *CMAJ Can Med Assoc J*. 2015;**187**(14):1054–1059. doi:10.1503/cmaj.141124

38. Pahnke WN, Kurland AA, Unger S, Savage C, Grof S. The experimental use of psychedelic (LSD) psychotherapy. *JAMA*. 1970;**212**(11):1856–1863.
39. Smith WR, Appelbaum PS. Novel ethical and policy issues in psychiatric uses of psychedelic substances. *Neuropharmacology*. 2022;**216**:109165. doi:10.1016/j.neuropharm.2022.109165
40. Smart RG, Storm T, Baker EF, Solursh L. A controlled study of lysergide in the treatment of alcoholism. 1. The effects on drinking behavior. *Q J Stud Alcohol*. 1966;**27**(3):469–482.
41. Strassman R. *DMT: The Spirit Molecule: A Doctor's Revolutionary Research into the Biology of Near-Death and Mystical Experiences*. Park Street Press; 2001. Accessed January 30, 2024. <http://catdir.loc.gov/catdir/enhancements/fy0644/00050498-t.html>
42. Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. *Psychopharmacology (Berl)*. 2006;**187**(3):268–283; discussion 284–292. doi:10.1007/s00213-006-0457-5
43. Griffiths RR, Richards WA, Johnson MW, McCann UD, Jesse R. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. *J Psychopharmacol Oxf Engl*. 2008;**22**(6):621–632. doi:10.1177/0269881108094300
44. Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. *J Clin Psychiatry*. 2006;**67**(11):1735–1740. doi:10.4088/jcp.v67n1110
45. Dos Santos RG, Osório FL, Crippa JAS, Hallak JEC. Antidepressive and anxiolytic effects of ayahuasca: a systematic literature review of animal and human studies. *Rev Bras Psiquiatr Sao Paulo Braz* 1999. 2016;**38**(1):65–72. doi:10.1590/1516-4446-2015-1701
46. Mithoefer MC, Feduccia AA, Jerome L, et al. MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. *Psychopharmacology (Berl)*. 2019;**236**(9):2735–2745. doi:10.1007/s00213-019-05249-5
47. Lee MA, Shlain B. *Acid Dreams: The Complete Social History of LSD: The CIA, the Sixties, and Beyond*. Rev. Evergreen ed. Grove Weidenfeld; 1992.
48. King LA, Corkery JM. An index of fatal toxicity for drugs of misuse. *Hum Psychopharmacol*. 2010;**25**(2):162–166. doi:10.1002/hup.1090
49. Nutt DJ. Equasy-- an overlooked addiction with implications for the current debate on drug harms. *J Psychopharmacol Oxf Engl*. 2009;**23**(1):3–5. doi:10.1177/0269881108099672
50. Nutt D, King LA, Saulsbury W, Blakemore C. Development of a rational scale to assess the harm of drugs of potential misuse. *Lancet Lond Engl*. 2007;**369**(9566):1047–1053. doi:10.1016/S0140-6736(07)60464-4
51. Nutt DJ, King LA, Phillips LD, Independent scientific committee on drugs. Drug harms in the UK: a multicriteria decision analysis. *Lancet Lond Engl*. 2010;**376**(9752):1558–1565. doi:10.1016/S0140-6736(10)61462-6
52. Yaden DB, Potash JB, Griffiths RR. Preparing for the bursting of the psychedelic hype bubble. *JAMA Psychiatry*. 2022;**79**(10):943–944. doi:10.1001/jamapsychiatry.2022.2546
53. Kious B, Schwartz Z, Lewis B. Should we be leery of being Leary? Concerns about psychedelic use by psychedelic researchers. *J Psychopharmacol Oxf Engl*. 2023;**37**(1):45–48. doi:10.1177/02698811221133461
54. Miron J, Partin E. Ending the war on drugs is an essential step toward racial justice. *Am J Bioeth*. 2021;**21**(4):1–3. doi:10.1080/15265161.2021.1895590
55. Torbay J. The work of Donald Ewen Cameron: from psychic driving to MK ultra. *Hist Psychiatry*. 2023;**34**(3):320–330. doi:10.1177/0957154X231163763
56. Grob CS, Danforth AL, Chopra GS, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. *Arch Gen Psychiatry*. 2011;**68**(1):71–78. doi:10.1001/archgenpsychiatry.2010.116
57. Dishotsky NI, Loughman WD, Mogar RE, Lipscomb WR. LSD and genetic damage. *Science*. 1971;**172**(3982):431–440. doi:10.1126/science.172.3982.431
58. Egozcue J, Irwin S, Maruffo CA. Chromosomal damage in LSD users. *JAMA*. 1968;**204**(3):214–218. doi:10.1001/jama.1968.03140160024006
59. van Elk M, Fried EI. History repeating: guidelines to address common problems in psychedelic science. *Ther Adv Psychopharmacol*. 2023;**13**:20451253231198466. doi:10.1177/20451253231198466
60. Michaels TI, Purdon J, Collins A, Williams MT. Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature. *BMC Psychiatry*. 2018;**18**(1):245. doi:10.1186/s12888-018-1824-6
61. Colagiuri B. Participant expectancies in double-blind randomized placebo-controlled trials: potential limitations to trial validity. *Clin Trials*. 2010;**7**(3):246–255. doi:10.1177/1740774510367916
62. Meir P, Taylor L, Soares JC, Meyer TD. Psychotherapists' openness to engage their patients in Psilocybin-Assisted Therapy for mental health treatment. *J Affect Disord*. 2023;**323**:748–754. doi:10.1016/j.jad.2022.12.050
63. Gold SM, Enck P, Hasselmann H, et al. Control conditions for randomised trials of behavioural interventions in psychiatry: a decision framework. *Lancet Psychiatry*. 2017;**4**(9):725–732. doi:10.1016/S2215-0366(17)30153-0
64. Constantino MJ, Arnkoff DB, Glass CR, Ametrano RM, Smith JZ. Expectations. *J Clin Psychol*. 2011;**67**(2):184–192. doi:10.1002/jclp.20754
65. Aday JS, Heifets BD, Pratscher SD, Bradley E, Rosen R, Woolley JD. Great expectations: recommendations for improving the methodological rigor of psychedelic clinical trials. *Psychopharmacology (Berl)*. 2022;**239**(6):1989–2010. doi:10.1007/s00213-022-06123-7
66. Wilsey B, Deutsch R, Marcotte TD. Maintenance of blinding in clinical trials and the implications for studying analgesia using cannabinoids. *Cannabis Cannabinoid Res*. 2016;**1**(1):139–148. doi:10.1089/can.2016.0016
67. Letheby C, Mattu J. Philosophy and classic psychedelics: A review of some emerging themes. *J Psychedelic Stud*. 2022;**5**(3):166–175. doi:10.1556/2054.2021.00191
68. Breeksema JJ, van Elk M. Working with weirdness: a response to “moving past mysticism in psychedelic science.” *ACS Pharmacol Transl Sci*. 2021;**4**(4):1471–1474. doi:10.1021/acspsci.1c00149
69. Vargas MV, Meyer R, Avanes AA, Rus M, Olson DE. Psychedelics and other psychoplastogens for treating mental illness. *Front Psychiatry*. 2021;**12**:727117. doi:10.3389/fpsy.2021.727117
70. Kaelen M, Giribaldi B, Raine J, et al. The hidden therapist: evidence for a central role of music in psychedelic therapy. *Psychopharmacology (Berl)*. 2018;**235**(2):505–519. doi:10.1007/s00213-017-4820-5
71. Anderson BT, Danforth AL, Grob CS. Psychedelic medicine: safety and ethical concerns. *Lancet Psychiatry* 2020;**7**(10):829–830. doi:10.1016/S2215-0366(20)30146-2
72. Smith WR, Sisti D. Ethics and ego dissolution: the case of psilocybin. *J Med Ethics*. 2021;**47**(12):807–814. doi:10.1136/medethics-2020-106070
73. Munafò A, Arillotta D, Mannaioni G, Schifano F, Bernardini R, Cantarella G. Psilocybin for depression: from credibility to feasibility, what's missing? *Pharmaceuticals*. 2023;**16**(1):68. doi:10.3390/ph16010068
74. Siegel JS, Daily JE, Perry DA, Nicol GE. Psychedelic drug legislative reform and legalization in the US. *JAMA Psychiatry*. 2023;**80**(1):77–83. doi:10.1001/jamapsychiatry.2022.4101
75. Alpert MD. Legalization of psychedelic substances. *JAMA*. 2021;**326**(23):2434. doi:10.1001/jama.2021.19369
76. Downey LA, Sarris J, Perkins D. Legalization of psychedelic substances. *JAMA*. 2021;**326**(23):2434–2435. doi:10.1001/jama.2021.19372
77. Marks M. Legalization of psychedelic substances. *JAMA*. 2021;**326**(23):2433–2434. doi:10.1001/jama.2021.19366
78. Marks M, Cohen IG. Psychedelic therapy: a roadmap for wider acceptance and utilization. *Nat Med*. 2021;**27**(10):1669–1671. doi:10.1038/s41591-021-01530-3
79. Smith WR, Appelbaum PS. Two models of legalization of psychedelic substances. *JAMA*. 2021;**326**(8):697–698. doi:10.1001/jama.2021.12481
80. Smith WR, Appelbaum PS. Legalization of psychedelic substances—reply. *JAMA*. 2021;**326**(23):2435–2436. doi:10.1001/jama.2021.19363
81. Yaden DB, Yaden ME, Griffiths RR. Psychedelics in psychiatry—keeping the renaissance from going off the rails. *JAMA Psychiatry*. 2021;**78**(5):469–470. doi:10.1001/jamapsychiatry.2020.3672
82. Koning E, Solmi M, Brietzke E. The Influence of Stakeholder Interests on Safety Outcome Reporting in Psychedelic Research and Implications for Science Communication. *Trends Psychiatry Psychother*. Published online August 1, 2024. doi:10.47626/2237-6089-2024-0866
83. Belouin SJ, Henningfield JE. Psychedelics: where we are now, why we got here, what we must do. *Neuropharmacology*. 2018;**142**:7–19. doi:10.1016/j.neuropharm.2018.02.018